Medical Access Program for Datopotamab Deruxtecan in NSCLC Patients

Conditions: Advanced Nonsquamous Non-Small Cell Lung Cancer; Metastatic Nonsquamous Non-Small Cell Lung Cancer Interventions: Drug: Datopotamab deruxtecan Sponsors: Daiichi Sankyo; AstraZeneca Available

https://clinicaltrials.gov/study/NCT06279728

Source: ClinicalTrials.gov - February 28, 2024 Category: Research Source Type: clinical trials